ASCO 2019: Form Biomarker Discovery to Photo-Immunotherapy

Published: July 17, 2019, 10:37 p.m.

b'In this episode of the Onco\\u2019Zine Brief Peter Hofland reports from the 2019 annual meeting of the American Society of Clinical Oncology \\u2013 ASCO \\u2013 which was held May 31st \\u2013 June 4th, 2019.

Hofland talks with:

- Dr. Hartmut Juhl, the Chief Executive Officer of Indivumed, a physician-led, integrated global oncology company. The company offers specialized products and services designed to support the discovery of biomarkers, drug development, clinical trials, and individualized treatment for patients with cancer, and

- Dr. Jeannie Hou, Vice President Clinical Development at Rakuten Medical, a company developing precision-targeted medicines through the development of a novel, proprietary photo-immunotherapy platform.

For more information, please visit Onco\'Zine at www.oncozine.com'